# JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors

> **NCT06226766** · PHASE1,PHASE2 · TERMINATED · sponsor: **Jiangsu Alphamab Biopharmaceuticals Co., Ltd** · enrollment: 11 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** JSKN033 Injection

## Key facts

- **NCT ID:** NCT06226766
- **Lead sponsor:** Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-01-18
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-07-31
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** the decision is based on a strategic realignment of our clinical trial priorities to optimize the overall development pathway for JSKN033
- **Last updated:** 2025-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06226766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06226766, "JSKN033 in Patients With Advanced or Metastatic Solid Malignant Tumors". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT06226766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*